Navigation Links
Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
Date:9/16/2009

nd deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer induced bone disease. Over 11,000 patients have been enrolled in the denosumab oncology clinical trials testing the drug for bone loss and destruction associated with cancer treatment-induced bone loss in breast and prostate cancers, for the prevention of skeletal related events due to the spread of cancer to the bone in multiple myeloma and multiple solid tumors, and for its potential to delay bone metastases in prostate cancer.

In two phase 3 skeletal related events studies reported to date, the incidence of adverse events and serious adverse events was consistent with what has previously been reported for denosumab and Zometa. Osteonecrosis of the jaw (ONJ) was seen infrequently in both treatment groups.

About Vectibix

Vectibix is the first fully human anti-EGFR approved by the U.S. Food and Drug Administration (FDA) for the treatment of mCRC. Vectibix was approved in the United States in September 2006 as a monotherapy for the treatment of patients with EGFR expressing mCRC after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

In December 2007, the European Commission granted a conditional marketing authorization for Vectibix as monotherapy for the treatment of patients with EGFR-expressing mCRC with wild-type KRAS genes after failure of standard chemotherapy regimens. Vectibix has been launched in over 20 countries, including Switzerland, Australia and Canada. Applications in the rest of the world are pending.

The effectiveness of Vectibix as a single agent for the treatment of EGFR-expressing, metastatic colorectal carcinoma is based on progression-free survival. Currently no
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. OmniPod(R) Insulin Management System Lets Team Type 1 Members Focus on Competing at Amgen Tour of California
4. Amgen to Present at the Barclays Capital Global Healthcare Conference
5. Amgen Announces Webcast of 2009 First Quarter Financial Results
6. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
7. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
8. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
9. Amgen Highlights Data to Be Presented at ASCO
10. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
11. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Summer is the dry ... Add to that a particularly long, dry and hot 2015 summer season and the ... fresh water advocate Sharon Kleyne will discuss the 2015 summer season and identify the ...
(Date:7/30/2015)... ... July 30, 2015 , ... The renowned Brain ... its history of funding brain aneurysm research. , Each year, the Brain ... toward scientific research directed at early detection, improved treatment modalities, and technological advances ...
(Date:7/30/2015)... ... ... PeopleKeys, a company with over 30 years of experience in behavioral analysis, today ... newest installment in their popular DISC for the Real World series, will air at ... is intended for people interested in training others to use DISC behavioral analysis as ...
(Date:7/29/2015)... ... , ... Drs. Hamstead are very excited to announce the expansion of ... in the clinic; massage therapy works very well alongside chiropractic care to restore balance ... AlignLife of Simpsonville to work alongside the doctors. Many people can benefit from massage ...
(Date:7/29/2015)... Los Angeles, CA (PRWEB) , ... July 29, 2015 , ... According to an ... published by the National Institutes of Health shows exactly what a person needs to do ... sex, height, and weight, the app will give informed estimates as to the number of ...
Breaking Medicine News(10 mins):Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 2Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 4Health News:PeopleKeys to Air “Managing Stress: Train the Trainer” DISC Webinar 2Health News:AlignLife of Simpsonville Hires Massage Therapist 2Health News:New NIH Body Weight Planner Illustrates the Need for Reduced Caloric Intake When Trying to Lose Weight, Says Beverly Hills Physicians 2
... Help Kids Worldwide, NEW YORK, Feb. 4 ... are being asked to submit creative,drawings for the 2008 ... One winner will be chosen from thousands of,entries and ... UNICEF,holiday greeting card, sold exclusively at Pier 1 Imports ...
... YORK, February 4, 2008 The Juvenile Diabetes ... of type 1 diabetes research, announced today that ... company based in Winston-Salem, N.C. that focuses on ... Through its Industry Discovery and Development Partnership Program, ...
... Feb. 4 Renowned esthetician, Karen,Dunlap, has developed ... recognized as the number-one most nutritious and powerful ... the dots between science and,nature, Dunlap discovered that ... -- magnifies its benefits. Her new signature facial, ...
... and 4 percent of former illicit drug users ... year following an organ transplant. These results are ... a journal by John Wiley & Sons. The ... ( http://www.interscience.wiley.com/journal/livertransplantation ). , Substance abuse can lead ...
... 2008 Contrary to previous research, older adults who use ... reduced risk of developing dementia or Alzheimers disease. This is ... the American Geriatrics Society that tracked patients using vitamin E ... than 5 years. The study also finds that the combined ...
... connecting patients and caregivers offers tips to families, ... ... helpful, CHICAGO, Feb. 4 What do you say, what ... or suffering from a serious,disease? To kick-off National Patient Recognition Week, ...
Cached Medicine News:Health News:Budding Young Artists Invited to Compete in 17th Annual Pier 1 Imports/UNICEF Greeting Card Contest 2Health News:Budding Young Artists Invited to Compete in 17th Annual Pier 1 Imports/UNICEF Greeting Card Contest 3Health News:JDRF partners with Plureon to explore generating insulin-producing cells from adult stem cells 2Health News:Breakthrough 'Acai Berry Anti-Aging Facial' Applies Benefits of Nature's Super-Food to the Skin 2Health News:Former substance abusers rarely relapse after organ transplantation 2Health News:Vitamin E or C does not reduce risk of dementia or Alzheimer's 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 3
(Date:7/29/2015)... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial ... quarter of 2015, the Company reported a net loss of $24.0 ... of $13.4 million, or $0.18 loss per share, for the same ... the Company reported a net loss of $25.2 million, or $0.30 ... or $0.35 loss per share, for the first half of last ...
(Date:7/29/2015)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today ... 2015 financial results after the market closes on Wednesday, ... by a conference call at 5:00 p.m. ET, which ... webcast. During the conference call, the company will review ... The conference call dial-in numbers are (877) ...
(Date:7/29/2015)... Calif., July 29, 2015  Depomed, Inc. (Nasdaq: ... achievements for the quarter ended June 30, 2015. ... the pain and neurology marketplace, with significant net product ... substantial value to our shareholders in both the immediate ... of Depomed. "Growth in the second quarter was led ...
Breaking Medicine Technology:Neurocrine Biosciences Reports Second Quarter 2015 Results 2Neurocrine Biosciences Reports Second Quarter 2015 Results 3Neurocrine Biosciences Reports Second Quarter 2015 Results 4Neurocrine Biosciences Reports Second Quarter 2015 Results 5Neurocrine Biosciences Reports Second Quarter 2015 Results 6Neurocrine Biosciences Reports Second Quarter 2015 Results 7Neurocrine Biosciences Reports Second Quarter 2015 Results 8Neurocrine Biosciences Reports Second Quarter 2015 Results 9Sangamo BioSciences Announces Second Quarter 2015 Conference Call and Webcast 2Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 2Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 3Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 4Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 5Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 6Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 7Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 8Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 9Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 10Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 11Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 12Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 13Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 14Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 15
... Beginning April 1, Highmark Blue Cross Blue Shield ... with primary immunodeficiency diseases and other rare disorders to ... (IgG - a blood plasma product), regardless of their ... patients who are being treated successfully with another brand ...
... ANGELES, March 21, 2011 Attorneys from Dallas, Heygood, Orr ... that will require executives from Watson Pharmaceuticals Inc. (NYSE: ... oath and produce key documents as part of a lawsuit over ... company,s fentanyl patch. Attorney Michael Heygood represents ...
Cached Medicine Technology:Despite New Changes, Highmark Policy Still Threatens Patients With Primary Immunodeficiency Diseases 2Despite New Changes, Highmark Policy Still Threatens Patients With Primary Immunodeficiency Diseases 3Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit 2
... Stryker Universal Wedge Screw is ... in cruciate reconstruction and is ... BTB grafts. The Universal Wedge ... and has blunt threads which ...
... combination of a screw and a barbed pin. ... resorbable pins for a hammertoe fixation and prevents ... use! Drill and tap the proximal phalanx. Drill ... the implant proximally. Press fit the barbed portion ...
The Stryker Graft Workstation offers the surgeon flexibility in graft preparation. The posts are interchangeable and the system adapts to both soft tissue and bone grafts selection. Sizing gauges off...
... The Stryker Conquest Suture ... instruments that pierce through ... suture through the tissue ... The Conquest Retrievers are ...
Medicine Products: